Home / Stocks / Aarti Drugs Ltd.
AARTIDRUGS

Aarti Drugs Ltd. Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹498.9

Change

-6.85 (-1.35%)

Open

₹507.45

Prev. Close

₹505.75

Day High

₹507.45

Day Low

₹494.1

Volume Analysis

Traded

268,291

Delivered

91,367

Delivery %

34.06%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (0)

No signal for this stock

Weaknesses (1)

  • •Promoter holding is falling

Opportunities (0)

No signal for this stock

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹519.55 ₹513.5 ₹506.2 ₹500.15 ₹492.85 ₹486.8 ₹479.5
Fibonacci ₹513.5 ₹508.4 ₹505.25 ₹500.15 ₹495.05 ₹491.9 ₹486.8
Camarilla ₹502.57 ₹501.35 ₹500.12 ₹500.15 ₹497.68 ₹496.45 ₹495.23

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

+19.74%

1 Week

-1.94%

1 Month

+28.38%

3 Months

+19.53%

6 Months

+27.94%

1 Year

+11.66%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹297.37

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

12.28%

Net margin 8.03% × asset turnover 0.84x × equity multiplier 1.82x

Company Overview

Sector

Healthcare

Market Cap

₹4,589 Cr

P/E (TTM)

19.9

ROE

13.4%

Book Value

₹184.0

Face Value

₹10.0

Source: Screener.in (Consolidated figures) — data as of 18 Nov 2026. Not investment advice.

TopFund Analysis

Aarti Drugs Ltd. lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 56/100. The strongest factor is Financial Strength (96/100), while Growth (12/100) is the weakest area to weigh before deciding. Notably: Promoter holding is falling.

TopFund Score — Fundamentals Quality

56/100 — Average

Data confidence: 80/100 (High Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

96

Growth

12

Valuation

51

Cash Flow

45

Corporate Governance

58

Momentum

88

Institutional Ownership

49

Business Quality

58

Risk & Volatility

62

Liquidity

42

From Screener.in

  • −Stock is trading at 2.73 times its book value
  • −Promoter holding has decreased over last quarter: -0.36%
  • −The company has delivered a poor sales growth of 3.55% over past five years.
  • −Company has a low return on equity of 13.3% over last 3 years.

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Promoter and Chairman Emeritus Chandrakant Vallabhaji Gogri died on November 15, 2026; he ceases to be a promoter.

US FDA inspected Pinnacle Life Science’s Baddi facility on Nov 2–6, 2026; received 3 Form 483 observations.

Audio recording of September 30, 2026 results conference call uploaded; transcript to follow.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 642 606 620 555 598 557 677 591 653 602 720 703 826
Expenses + 565 536 534 490 531 495 583 516 569 547 624 605 691
Operating Profit 76 70 86 65 67 62 93 74 84 55 96 98 135
OPM % 12.0% 12.0% 14.0% 12.0% 11.0% 11.0% 14.0% 13.0% 13.0% 9.0% 13.0% 14.0% 16.0%
Other Income + 1 2 1 1 1 12 2 0 0 1 1 -1 3
Interest 8 8 9 9 9 9 9 9 8 9 8 9 10
Depreciation 13 13 14 13 14 14 15 15 16 18 18 18 19
Profit before tax 56 52 64 44 46 51 71 51 60 29 70 69 109
Tax % 30.0% 29.0% 26.0% 24.0% 24.0% 27.0% 12.0% -6.0% 25.0% -40.0% 21.0% 28.0% 24.0%
Net Profit + 40 37 47 33 35 37 63 54 45 41 55 50 83
EPS in Rs 4 4 5 4 4 4 7 6 5 4 6 6 9
Raw PDF — — — — — — — — — — — — —
YoY Sales growth -7 -9 -16 -16 -7 -8 9 6 9 8 6 19 27

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 1,097 1,140 1,195 1,244 1,561 1,806 2,155 2,489 2,716 2,529 2,387 2,565 2,851
Expenses + 925 960 1,005 1,042 1,350 1,541 1,714 2,156 2,407 2,208 2,097 2,254 2,467
Operating Profit 172 180 190 202 211 266 440 333 309 321 290 312 384
OPM % 16.0% 16.0% 16.0% 16.0% 14.0% 15.0% 20.0% 13.0% 11.0% 13.0% 12.0% 12.0% 13.0%
Other Income + 1 0 4 1 6 6 5 11 2 4 16 2 3
Interest 42 48 40 38 44 37 26 24 37 38 39 36 36
Depreciation 31 37 38 40 43 49 50 50 50 51 56 67 73
Profit before tax 100 95 116 125 131 185 369 270 224 236 212 211 278
Tax % 23.0% 28.0% 29.0% 34.0% 32.0% 24.0% 24.0% 24.0% 26.0% 27.0% 21.0% 8.0% —
Net Profit + 77 69 82 82 90 141 280 205 166 172 168 195 229
EPS in Rs 8 7 9 9 10 15 30 22 18 19 18 21 25
Dividend Payout % 41.0% 24.0% 3.0% 3.0% 3.0% 3.0% 8.0% 5.0% 6.0% 5.0% 5.0% 9.0% —
Sales growth — 4 5 4 26 16 19 15 9 -7 -6 7 15

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 284 333 376 432 520 629 820 944 1,100 1,190 1,278 1,458 1,590
Borrowings + 448 483 480 546 507 389 351 543 609 564 615 577 620
Other Liabilities + 248 261 311 388 405 535 502 629 620 587 591 690 753
Total Liabilities 1,004 1,102 1,191 1,389 1,455 1,576 1,766 2,208 2,421 2,432 2,575 2,815 3,054
Fixed Assets + 448 493 581 602 625 644 665 690 676 811 866 1,086 1,113
CWIP 16 34 14 28 33 12 19 77 210 261 330 214 236
Investments 5 5 12 11 12 13 17 19 19 20 22 27 28
Other Assets + 534 570 584 748 785 907 1,064 1,422 1,516 1,340 1,356 1,488 1,677
Total Assets 1,004 1,102 1,191 1,389 1,455 1,576 1,766 2,208 2,421 2,432 2,575 2,815 3,054
Equity Capital 24 24 24 24 24 23 93 93 93 92 91 91 91

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 105 133 175 70 143 251 155 70 133 359 245 254
Cash from Investing Activity + -107 -99 -107 -74 -62 -33 -72 -150 -164 -224 -165 -173
Cash from Financing Activity + 1 -33 -68 4 -80 -215 -81 92 17 -136 -82 -77
Net Cash Flow -1 1 0 0 1 2 2 13 -14 -1 -2 3
Free Cash Flow -2 34 68 -5 80 214 78 -82 -31 133 67 80
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 69 85 103 47 82 110 57 46 62 131 103 80

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 57.47% → 54.07%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 35.16% 34.3% 34.01% 34.01% 33.58% 32.57% 32.58% 32.7% 32.71% 33.19% 33.76% 33.42%
Promoters 57.47% 57.13% 55.67% 55.64% 55.38% 55.48% 55.23% 54.72% 55.03% 55.03% 54.43% 54.07%
FII 2.1% 2.56% 2.95% 2.5% 2.28% 2.25% 2.26% 2.68% 2.15% 1.57% 1.52% 2.26%
DII 5.26% 5.99% 7.35% 7.83% 8.77% 9.7% 9.94% 9.9% 10.12% 10.22% 10.29% 10.24%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Aarti Drugs Ltd. (this stock) 4,589 19.9 2.73 13.4%
Gujarat Themis Biosyn Ltd 4,659 239.0 4.55 16.2%
Zota Health Care Limited 4,492 — 7.17 -15.0%
Sms Pharmaceuticals Ltd. 4,758 40.7 5.64 14.3%
Gufic Biosciences Ltd. 4,415 55.1 6.21 10.1%
Kwality Pharmaceuticals L 4,370 45.3 11.31 22.6%
Rpg Life Sciences Ltd 4,220 36.8 6.13 19.3%

Which Mutual Funds Hold Aarti Drugs Ltd.?

Frequently Asked Questions about Aarti Drugs Ltd.

Community Sentiment

What are other investors saying about Aarti Drugs Ltd.?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.